In this issue of CARDIOVASC, a significant focus is on the procedure surrounding the occurrence of thrombosis and pulmonary embolism.
The current situation, with approval of several new anticoagulants for the treatment of thromboembolic disease, suggests that the management of thromboembolism will change in the coming months to years. Therefore, we would like to introduce you to some practical points in three different reviews. Michael Baumann, MD, highlights the possibilities and difficulties that can arise in the context of clarifying thromboembolism in terms of hypercoagulability. Great emphasis is placed on practical aspects of pulmonary embolism recognition, diagnosis, and treatment in the work of Thomas Lehmann, MD. The purpose of this review is to highlight the difficulties in recognizing and treating pulmonary embolism in the prehospital setting to ensure the best possible outcome in these patients.
Finally, the paper by Dr. Nazanin Sédille-Mostafaie describes the properties and indications of the three oral anticoagulants newly approved in Switzerland and points out possible relevant problems in the use of these substances. It should be noted that the new substances represent an efficient and safe alternative to the previously available anticoagulants in the approved indications. Now I wish you what I hope will be an exciting read.
Kind regards
Prof. Dr. med. Wolfgang Korte
